Jéssica Ferreira Vieira

Jéssica Ferreira Vieira

Auto-generated profile, based on publicly available information

Jéssica Ferreira Vieira

Oncology Research Institute (Instituto de Pesquisa em Oncologia, IPON), Federal University of the Triângulo Mineiro (Universidade Federal do Triângulo Mineiro, UFTM), Uberaba 38025-350, Minas Gerais, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Open access
PDF file
NTNelson Ranieri Tirone
Nelson Ranieri Tirone
CCCarolina Guissoni Campos
Carolina Guissoni Campos
KFKézia Jesus Aguiar Ferreira
Kézia Jesus Aguiar Ferreira
LSLéticia Montes Stark
Léticia Montes Stark
JVJéssica Ferreira Vieira
Jéssica Ferreira Vieira
MMMarcia Michelin
Marcia Michelin
Objective The aim of the present study was to compare the local and systemic expression of the factors linked to the interferon alpha (IFN-α) activation pathway in different degrees of cervical intraepithelial neoplasia (CIN) and cervical cancer. Methods A total of 128 patients with CIN I, CIN II, CIN III and cervical cancer was evaluated. The real-time polymerase chain reaction (RT-PCR) technique was used to evaluate the gene expression of IFNR1, IFNR2, IFN-α, oligoadenylate synthase (2'5′OAS), cytokine signal suppressor 1 (SOCS) 1, SOCS3, signal transducer and transcription activator 1 (STAT1), and IRF9 from 128 biopsies. A total of 46 out of 128 samples were evaluated by flow cytometry for IFNAR1, IFNAR2, STAT1, IRF7 and IFN-α in peripheral blood cells. Results Patients with CIN II and III (63 samples) had a low local expression of IFNR1, but not IFNR2. Patients with some degree of injury showed high expression of SOCS1 and SOCS3. Systemically, patients with CIN II and III (20 samples) had a significant increase in IFNR1, IFNR2, STAT1, IRF7, and IFN-α in helper, cytotoxic T lymphocytes, and in monocytes. Conclusion Patients with high-grade lesions have increased systemic expression of IFN-α and its activation pathways in helper and cytotoxic T lymphocytes, as well as in monocytes due to an exacerbation of the immune response in these patients. This phenomenon is not accompanied by resolution of the lesion due to a defect in the IFN-α activation pathway that revealed by low local IFNAR1 expression and high local expression of SOCS1 and SOCS3.

1 January 2024 in Journal of Nutrition and Metabolism
Verified
Journal Article
Open access
GGGoncalves Goncalves
Goncalves Goncalves
JVJéssica F. Vieira
Jéssica F. Vieira
ARAna Carolina N. Rodrigues
Ana Carolina N. Rodrigues
EMEddie F. C. Murta
Eddie F. C. Murta
JMJulio Sergio Marchini
Julio Sergio Marchini
GPGuilherme Vannucchi Portari
Guilherme Vannucchi Portari
Background. Benfotiamine, a synthetic analog of thiamine, offers greater bioavailability compared to other thiamine salts and increases thiamine stores upon oral intake. Thiamine is essential for energy metabolism. This study aimed to evaluate the effects of oral benfotiamine supplementation on energy metabolism, particularly the Krebs cycle function, in the muscle of endurance‐trained mice, and to assess its impact on endurance performance. Methods. Twenty‐five mice were randomly assigned to four groups: a standard diet with sedentary behavior (Sta‐Sed), a benfotiamine‐supplemented diet with sedentary behavior (Ben‐Sed), a standard diet with swimming training (Sta‐Tr), and a benfotiamine‐supplemented diet with swimming training (Ben‐Tr). The trained groups underwent five weekly swimming sessions for six weeks, followed by an exhaustive test. Thiamine and its esters were measured in erythrocytes and gastrocnemius muscle. Gene expression of pyruvate dehydrogenase (PDHa) and alpha‐ketoglutarate dehydrogenase (OGDH), along with levels of pyruvic, lactic, and hydroxybutyric acids in muscle, was analyzed. Results. The benfotiamine‐supplemented groups had higher thiamine levels in erythrocytes and muscles compared to the standard‐diet groups. No differences were observed in PDHa and OGDH gene expression. The Ben‐Tr group exhibited increased muscle lactic acid levels and a higher lactic acid to pyruvic acid ratio compared to the sedentary groups. Hydroxybutyric acid levels were also elevated in the Ben‐Tr group. No significant differences in exhaustive test duration were found between the groups. Conclusion. Benfotiamine supplementation increases thiamine levels in erythrocytes and muscle but does not affect the gene expression of thiamine‐dependent enzymes. Although it alters energy metabolism in trained muscle, it does not enhance endurance performance in mice.

13 April 2026 in Exploration of Immunology
Verified
Journal Article
Open access
PDF file
MAMurilo Porfírio de Aguiar
Murilo Porfírio de Aguiar
JVJulia Hailer Vieira
Julia Hailer Vieira
JVJéssica Ferreira Vieira
Jéssica Ferreira Vieira
Breast cancer exhibits substantial clinical and molecular heterogeneity, partly shaped by interactions between tumor biology and the host immune system. Germline variants in immune-related genes may influence inflammatory tone, immune regulation, and tumor-immune interactions. However, evidence linking inherited immune genetic variation to breast cancer risk and clinical behavior remains fragmented and heterogeneous across studies. We conducted a structured integrative review of 33 human genetic associations evaluating germline variants in immune-related genes and their associations with breast cancer risk, prognosis, and clinicopathological features. Data were synthesized using a comparative, pathway-oriented analytic framework. Variants in cytokine genes, particularly TGFB1, IL6, IL1B, and IL10, were the most frequently associated with susceptibility, although effect directions varied across populations and genetic models. In contrast, variants in chemokine pathways (CXCL12) and immune checkpoint regulator genes (B7-H4/VTCN1, PD-1/PDCD1) showed consistent associations with tumor progression, immune evasion, and subtype-specific clinical features, including human epidermal growth factor receptor 2 (HER2)-positive disease and metastatic presentation. Across studies, substantial heterogeneity was observed, driven by differences in ethnic composition, sample size, methodological design, and deviations from the Hardy-Weinberg equilibrium. The findings support a pathway-oriented interpretation in which germline immune variation differentially influences immune regulation and tumor progression rather than uniformly determining disease risk. While inflammatory and immunoregulatory pathways appear to shape basal immune tone, immune effector function is less consistently associated with germline variation. Further progress will require extensive, multiethnic studies integrating genetic, transcriptomic, and functional data to clarify how inherited immune variation contributes to breast cancer biology.

25 June 2026 in Einstein (São Paulo)
Verified
Journal Article
Closed access
MAMurilo Porfírio de Aguiar
Murilo Porfírio de Aguiar
EGEleni Solange de Brito Gomes
Eleni Solange de Brito Gomes
JVJéssica Ferreira Vieira
Jéssica Ferreira Vieira

5 August 2026 in Exploration of Targeted Anti-tumor Therapy
Verified
Journal Article
Open access
PDF file
TDTauana Christina Dias
Tauana Christina Dias
JVJéssica Ferreira Vieira
Jéssica Ferreira Vieira
KTKatiane Tostes
Katiane Tostes
PSPolyana Barbosa Silva
Polyana Barbosa Silva
ALAngela Maria Moed Lopes
Angela Maria Moed Lopes
MMMarcia Michelin
Marcia Michelin
Aim: Breast cancer remains a major cause of cancer-related mortality in women, particularly in advanced stages where therapeutic options are limited. While immune checkpoint inhibitors (ICIs) have improved outcomes in a subset of patients, many do not respond, highlighting the need for alternative immunotherapeutic strategies. This study evaluated the effect of dendritic cell (DC)-based immunotherapy on tumor growth and on the inflammatory profile of peritoneal myeloid cells in a 4T1 murine breast cancer model. Methods: BALB/c mice bearing 4T1 breast tumors were treated with bone marrow-derived DC-based immunotherapy. Tumor volume was monitored over time, and CD14+ cells obtained from peritoneal lavage were analyzed by flow cytometry for the cytokines IL-12, IL-17, and TNF-α and the transcription factors RORγT and GATA3. Results: DC-based immunotherapy was associated with a non-significant trend toward reduced tumor volume and a marked suppression of key proinflammatory cytokines: IL-12 (P < 0.0005), IL-17 (P < 0.0001), and TNF-α (P < 0.0001). Expression of the transcription factors RORγT and GATA3, associated with Th17 and Th2 differentiation, was also downregulated (P < 0.0001). These immunological effects were observed in CD14+ myeloid cells from the peritoneal compartment. Conclusions: DC-based immunotherapy modulates the systemic/peritoneal inflammatory profile and attenuates tumor-promoting inflammation. This strategy may offer therapeutic benefit for patients with breast cancer who are unresponsive to conventional or ICI-based treatments and supports its further evaluation in translational studies.

2 October 2021 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
JVJéssica Ferreira Vieira
Jéssica Ferreira Vieira
EMEddie Fernando Candido Murta
Eddie Fernando Candido Murta
MMMarcia Michelin
Marcia Michelin
Dendritic cell vaccines have demonstrated promising results for poorly immunogenic tumors, which may promote the generation of better immune responses in the tumor microenvironment. However, the vaccine has little been evaluated as a prophylactic option. Therefore, this study evaluates the influence of prophylactic dendritic cell vaccination on the antitumor immune response in the tumor microenvironment and on tumor growth, in an experimental model with breast cancer induced by 4T1. Therefore, Balb/c mice were separated into a vaccinated group and an unvaccinated group. Dendritic cell vaccine was differentiated and matured ex vivo from bone marrow. During the experimental period, the tumor volumes were checked periodically. The tumors were evaluated for immune cells (helper T lymphocytes and cytotoxic T lymphocytes), helper T cells (Th1, Th2, Th17, and Treg), TNF-α, and IFN-γ synthesis by Th1 and cytotoxic T lymphocytes. The vaccinated group had decreased tumor volume (14.0, 0-131.7) compared to the unvaccinated group (89.59, 0.1250-459.6) (p=0.0421). The Th1, Th2, Th17, Treg, cytotoxic T subtypes, including TNF-α and IFN-γ produced by Th1 and T cytotoxic, showed a significant increase in the vaccinated group, as did the balance of Th1/Th2 and Th1/Treg. The results showed that prophylactic vaccination with dendritic cells showed a considerable antitumor effect in the studied model by promoting an increase in the activation of important cells in the immune response and a reduction in tumor volume. The data provide evidence for timely activation of immune surveillance in the absence of tumor burden.